Medicilon provides different kinds of animal disease models for pharmacology services such as Cancer Xenograft Models, Neurological Disorders Models, Inflammation & Immunological Disease Models and Metabolic Disease Models.
Dr. Chunlin Chen, Medicilon CEO, was appointed as Chairman of the Drug Metabolism Professional Committee of 4th Shanghai Pharmacological Society.
Recently, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Science and South China Center for Innovative Pharmaceuticals' “Class 1.1 piperazine da ketone chemical drugs” (AD16) was officially accepted by CFDA for clinical trial.
The year of 2014 is a successful year to Medicilon. Medicilon would like to take this opportunity to thank you for the support from all the clients and wish them have a happy new year.
The “Cooperation Advantage and Innovative Technology of CRO’s New Drug Development Forum” was held in Nanjing BSK Community on December 5. The CEO of Medicilon, Dr. Chunlin Chen, was invited to give a speech in the forum.